Market Place
Sourcing Support
CNS Pharmaceuticals Prices $3 Million Direct Offering Of Stock
23 Oct 2024 //
ACCESSWIRE
CNS Pharmaceuticals Participate Virtual Investor KOL Connect Segment
10 Oct 2024 //
ACCESSWIRE
CNS Pharmaceuticals To Participate In 2024 Healthcare Summit
08 Oct 2024 //
ACCESSWIRE
CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement
12 Sep 2024 //
ACCESSWIRE
CNS Pharma To Participate In Webull Corporate Connect Biotech Webinar
27 Aug 2024 //
ACCESSWIRE
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
22 Aug 2024 //
ACCESSWIRE
CNS Pharma In-Licenses Novel Abeotaxane For Brain Malignancies Treatment
30 Jul 2024 //
ACCESSWIRE
CNS Pharmaceuticals To Present At 2024 SNO/ASCO CNS Cancer Conference
25 Jul 2024 //
ACCESSWIRE
CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series
16 Jul 2024 //
ACCESSWIRE
CNS Announces Pricing of Registered Direct Offering and Private Placement
03 Jul 2024 //
ACCESSWIRE
CNS Pharmaceuticals Announces Pricing Of Direct Offering, Private Placement
26 Jun 2024 //
ACCESSWIRE
CNS Pharmaceuticals Prices Registered Direct Concurrent Private Offering
14 Jun 2024 //
ACCESSWIRE
CNS Pharmaceuticals Announces Reverse Stock Split
03 Jun 2024 //
ACCESSWIRE
CNS Pharma To Present At AGP Healthcare Showcase
20 May 2024 //
ACCESSWIRE
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
16 May 2024 //
ACCESSWIRE
CNS Pharmaceuticals to Present at the LSX World Congress 2024
23 Apr 2024 //
ACCESSWIRE
CNS Pharma At Virtual Investor Lunch Break Event
22 Apr 2024 //
ACCESSWIRE
CNS Pharmaceuticals to Present at Two Investor Conferences in April
01 Apr 2024 //
ACCESSWIRE
CNS Pharmaceuticals Reports Full Year 2023 Financial Results
01 Apr 2024 //
ACCESSWIRE
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering
29 Jan 2024 //
ACCESSWIRE
Amy Mahery, to Join CNS Pharmaceuticals Board of Directors
18 Jan 2024 //
ACCESSWIRE
CNS Achieves Completion of Enrollment in Pivotal Study of Berubicin
17 Jan 2024 //
ACCESSWIRE
CNS Announces Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
18 Dec 2023 //
ACCESSWIRE
CNS Pharma Presents Safety Data from Pivotal Study Evaluating Berubicin
22 Nov 2023 //
ACCESSWIRE
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results
15 Nov 2023 //
ACCESSWIRE
CNS Pharma to Participate at the Virtual Investor Ask the CEO Conference
19 Oct 2023 //
ACCESSWIRE
CNS Pharmaceuticals` Ongoing Potentially Pivotal Study of Berubicin
11 Oct 2023 //
ACCESSWIRE
CNS Reaches Milestone with Enrollment of 200 Patients in Study of Berubicin
07 Sep 2023 //
ACCESSWIRE
CNS Pharma to Present at the H.C. Wainwright 25th Annual Investment Conference
05 Sep 2023 //
ACCESSWIRE
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
ACCESSWIRE
CNS Pharmaceuticals Presents Results from Pivotal Study of Berubicin
14 Aug 2023 //
ACCESSWIRE
CNS Pharmaceuticals Provides Clinical Trial Update for Study with Berubicin
03 Aug 2023 //
ACCESSWIRE
CNS Pharma Announces Acceptance of Abstract for Presentation at SNO/ASCO
27 Jul 2023 //
ACCESSWIRE
CNS Pharma to Participate in the Virtual Investor Summer Spotlight Series
05 Jul 2023 //
ACCESSWIRE
CNS Pharma to Participate in the Healthcare Conference Presented by Maxim Group
14 Jun 2023 //
ACCESSWIRE
CNS Achieves Over 50% Completion of Enrollment in Study with Berubicin for GBM
25 May 2023 //
ACCESSWIRE
CNS Pharmaceuticals Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
ACCESSWIRE
CNS Pharmaceuticals Invg Potential Naked Short Selling; Retains Intelligence
03 May 2023 //
BUSINESSWIRE
Patients Enrolled in CNS Pharmac’ Pivotal Study Evaluating Berubicin
10 Apr 2023 //
ACCESSWIRE
CNS Pharmaceuticals Receives Approval for Berubicin for the Treatment of GBM
06 Apr 2023 //
ACCESSWIRE
CNS Pharmaceuticals Reports Full Year 2022 Financial Results
03 Apr 2023 //
ACCESSWIRE
CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues
13 Mar 2023 //
PR NEWSWIRE
CNS Continues Momentum in Potentially Pivotal Global Trial Evaluating Berubicin
09 Mar 2023 //
PR NEWSWIRE
CNS Announces First Patient Enrolled in Spain in Trial Evaluating Berubicin
07 Feb 2023 //
PR NEWSWIRE
CNS Announces Investigator-Initiated Ph1b/2 Trial to be Conducted at Pomeranian University
12 Jan 2023 //
PR NEWSWIRE
CNS Pharma to Present at the Virtual Investor 2023 Companies to Watch Event
05 Jan 2023 //
PR NEWSWIRE
CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of theBOD
03 Jan 2023 //
PR NEWSWIRE
Federal court halts delisting of Jazz narcolepsy drug patent from Orange Book
15 Dec 2022 //
ENDPTS
CNS Announces Results from Potentially Pivotal Trial Evaluating Berubicin
08 Dec 2022 //
PRNEWSWIRE
CNS Pharma Announces Pricing of $6.0 Million Public Offering At a Premium
30 Nov 2022 //
PRNEWSWIRE
CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
PRNEWSWIRE
CNS Announces Dosing of Patient in Europe in Trial Evaluating Berubicin
02 Nov 2022 //
PRNEWSWIRE
CNS doses first subject in brain cancer treatment trial in France
02 Nov 2022 //
CLINICALTRIALSARENA
CNS Pharmaceuticals to Participate in The ABTA for Brain Tumors 5K (BT5K) Run
10 Oct 2022 //
PRNEWSWIRE
CNS activates first European sites for glioblastoma multiforme trial
29 Sep 2022 //
CLINICALTRIALSARENA
CNS Pharmaceuticals Announces Activation of First Trial Sites in Europe
28 Sep 2022 //
PRNEWSWIRE
CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology
23 Sep 2022 //
PRNEWSWIRE
CNS to Present at the H.C. Wainwright 24th Annual Global Investment Conference
07 Sep 2022 //
PRNEWSWIRE
CNS Pharma Urges Shareholders to Vote in Favor of Proxy Proposals
25 Jul 2022 //
PRNEWSWIRE
CNS Pharma Bags Approval from FDA for Protocol Amendment to Trial of Berubicin
23 Jun 2022 //
PRNEWSWIRE
